Treatment
Immunoglobulins clinical trials
We’re tracking 79 recruiting studies that include Immunoglobulins, each written for real people, not researchers, below.
Recruiting studies
- NCT05003986RecruitingPhase 2
Sparsentan for children with protein leaking kidney diseases
This Phase 2 study tests sparsentan in children with certain kidney diseases that cause high amounts of protein in the urine. It aims to see if the medicine can reduce kidney damage signals and protein leakage compared with standard care.
Los Angeles, CaliforniaAges 1–17 - NCT05325008RecruitingPhase 3
IVIG treatment for BK virus after kidney transplant
This Phase 3 trial tests IVIG (an antibody medicine given through a vein) to treat BK virus infection after kidney or pancreas-kidney transplant. It may help lower the BK virus in the blood and protect the transplanted kidney.
Canberra, Australian Capital TerritoryAges 2 years+ - NCT05357781Recruiting
Test immunoglobulin treatment for fatigue in multiple sclerosis
This trial studies whether giving immunoglobulins (antibody medicines) can improve fatigue in people with multiple sclerosis (MS). It will enroll only people whose MS and fatigue are stable and meet specific blood/health criteria.
Bern, Canton of BernAges 18–65 - NCT05584631RecruitingPhase 1
Switching IVIG to weekly SCIG for CIDP treatment
This Phase 1 study compares IVIG given through an IV versus SCIG given under the skin, for people with CIDP. It aims to find the right weekly SCIG dose based on your current IVIG dose, which could make treatment more convenient.
New Brunswick, New JerseyAges 18–65 - NCT05775042RecruitingPhase 2
CM338 for immunoglobulin A kidney disease
This Phase 2 study tests CM338 to see if it can help people with immunoglobulin A (IgA) nephropathy, a kidney condition. You may be able to join if you meet age, medication, and health criteria and can follow study safety rules.
Beijing, Beijing MunicipalityAges 18–75 - NCT06054373Recruiting
Immunoglobulin levels in autoimmune diseases
This study looks at the distribution of a type of immune protein called immunoglobulin in people with autoimmune diseases or lymphoma. It aims to understand how these proteins are altered in these conditions.
AmiensAges 18 years+ - NCT06183645Recruiting
Predicting CIDP decline during IVIg treatment changes
This study looks at people with CIDP who are stable on IVIg treatment to see if we can predict when they might get worse if their treatment is adjusted. It aims to make treatment management easier and more personalized.
Liège, LiègeAges 18–99 - NCT06350630RecruitingPhase 2
Hydroxychloroquine for IgA nephropathy
This trial tests whether hydroxychloroquine can help slow kidney damage in people with IgA nephropathy. You may qualify if you have this kidney disease, are already on two standard medicines (RAAS inhibitors and SGLT2 inhibitors), and have ongoing protein in your urine.
Clermont-FerrandAges 18 years+ - NCT06466135RecruitingPhase 2
Study of WAL0921 for glomerular kidney diseases
This study tests a new drug called WAL0921 for people with certain types of kidney disease. The goal is to see if it can help protect kidney function.
Los Angeles, CaliforniaAges 18–75 - NCT06573723Recruiting
Rare disease registry at Hospital Italiano
This study collects information from patients with certain rare diseases to better understand them. If you have one of these conditions and receive care at Hospital Italiano de Buenos Aires, you may be able to join.
Buenos Aires, Buenos AiresAges Any age - NCT06661603Recruiting
Yoga and meditation for medical students' health
This study looks at how doing yoga and meditation might affect stress hormones, immune markers, and health in medical students. If you are a medical student at the University of Pecs, you may be able to join and learn how these practices can help your well-being.
Pécs, PécsAges 18–40 - NCT06676579RecruitingPhase 2
Avacopan for active IgA kidney disease with crescents
This trial tests if avacopan, a targeted anti-inflammatory drug, can safely treat a severe form of IgA nephropathy (IgAN) where small crescents form in the kidney filters. It may help reduce protein leakage and preserve kidney function.
Jacksonville, FloridaAges 18 years+ - NCT06686927RecruitingPhase 2
Steroids, IVIG, and romiplostim for severe ITP
This study tests a combination of three treatments—steroids, IVIG, and romiplostim (Nplate)—for adults with severe, newly diagnosed ITP that hasn't responded well to standard therapy. The goal is to see if this triple therapy can quickly raise platelet counts and stop bleeding.
Wuhan, HubeiAges 18–75 - NCT07541287RecruitingPhase 2
JADE101 for IgA Nephropathy Kidney Disease
This study tests whether JADE101, a new medicine, can help slow kidney damage in people with IgA nephropathy (a type of kidney disease caused by immune system problems). You'll take it alongside your current blood pressure medications for about 48 weeks.
Chula Vista, CaliforniaAges 18–60 - NCT06740526RecruitingPhase 2
A trial of sibeprenlimab for IgA nephropathy kidney tissue
This study tests a drug called sibeprenlimab to see how it affects kidney tissue in people with IgA nephropathy (IgAN), a condition where antibodies build up in the kidneys. It may help protect your kidneys if your disease is still active.
Denver, ColoradoAges 16 years+ - NCT06834035RecruitingPhase 1/Phase 2
IV IgG for collagen VII antibodies in dystrophic epidermolysis bullosa
This trial tests if intravenous immunoglobulin (IV IgG) can help people with a form of epidermolysis bullosa who have antibodies against collagen VII. It may reduce blistering and improve wound healing.
Redwood City, CaliforniaAges 6 years+ - NCT06925360RecruitingPhase 2
IVIG for lung disease in premature babies
This trial tests if intravenous immunoglobulin (IVIG) can help prevent or treat bronchopulmonary dysplasia (BPD), a lung condition in premature babies. It is for very preterm infants born between 25 and 29 weeks who show early signs of BPD and are enrolled in the first day of life.
Shanghai, Shanghai MunicipalityAges Up to 2 months - NCT06958796RecruitingPhase 4
CMV immunoglobulin to prevent disease after transplant
This trial tests whether giving CMV immunoglobulin (an antibody medicine) after transplant can help prevent a serious CMV infection in people who receive a kidney or liver from a CMV-positive donor. You might be eligible if you are getting one of these transplants and are at high risk for CMV.
Boston, MassachusettsAges 18–75 - NCT06989541Recruiting
Immunoglobulin for low antibodies after CAR T-cell therapy
This trial tests whether giving immunoglobulin (a treatment that boosts your antibodies) can help people who developed very low antibody levels after CAR T-cell therapy for cancer. It may help prevent infections and improve recovery.
Edmonton, AlbertaAges 18 years+ - NCT06994845RecruitingPhase 3
Testing iptacopan for children with IgA nephropathy
This study tests a new medicine called iptacopan to see if it helps children with IgA nephropathy (a kidney disease). Kids who join will receive the study treatment and be monitored for safety and effectiveness.
Aurora, ColoradoAges 2–18 - NCT07187531RecruitingPhase 2
Testing a new drug to slow type 1 diabetes progression
This trial tests an experimental drug called SAB-142 to see if it can slow down or stop the progression of type 1 diabetes. It is designed for people who were recently diagnosed and still produce some insulin on their own.
San Francisco, CaliforniaAges 5–40 - NCT07232459Recruiting
PET imaging for amyloidosis in the heart
This study tests a new PET imaging tracer called [18F]FT8 to see if it can better detect amyloid protein buildup in the heart. It may help doctors diagnose and monitor cardiac amyloidosis more accurately.
Hefei, AnhuiAges 18 years+ - NCT07680413Recruiting
Study of Histoglob for chronic hives in real-life care
This trial is looking at how well the drug Histoglob (Immunoglobulin-Histamine Complex) works for people with chronic urticaria (hives that last a long time). It's for patients who are already on a first-line treatment and are starting Histoglob for the first time as part of their regular care.
Ahmedabad, GujaratAges 13 years+ - NCT07273903Recruiting
Tracking CIDP treatment with a smartwatch
This trial tests whether a smartwatch can help monitor how well subcutaneous immunoglobulin (fSCIG) works for people with CIDP who recently switched from IVIG or plan to switch. It aims to make treatment tracking easier and more convenient.
Düsseldorf, North Rhine-WestphaliaAges 18 years+
Common questions
- Are there clinical trials studying Immunoglobulins?
- Yes. Clin2 currently lists 79 recruiting studies that include Immunoglobulins, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Immunoglobulins trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Immunoglobulins an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Immunoglobulins or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.